Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
New York, USA, July 01, 2024 (GLOBE NEWSWIRE) -- Advanced Kidney Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 50+ Companies Working in...
-
LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent...
-
New York, USA, May 15, 2024 (GLOBE NEWSWIRE) -- JAK Inhibitor Market to Register Immense Growth by 2034, Predicts DelveInsight | Key Companies - Eli Lilly and Company, Incyte Corporation, Dompé...
-
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Human Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Human Vaccines Market to Reach...
-
New York, USA, April 24, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the...
-
EGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsight
New York, USA, April 22, 2024 (GLOBE NEWSWIRE) -- EGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the...
-
New York, USA, April 17, 2024 (GLOBE NEWSWIRE) -- HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen...
-
New York, USA, April 09, 2024 (GLOBE NEWSWIRE) -- TROP-2 Inhibitors Market to Boost by 2034, Predicts DelveInsight | Key Companies to Look Out - Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck,...
-
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical...
-
BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...